Gemcitabine, Trastuzumab, and Pertuzumab in the Treatment of Metastatic HER2-Positive Breast Cancer After Prior Trastuzumab/Pertuzumab, or Pertuzumab Based Therapy

计划入组 45 人 · 首次发布于 2014 年 9 月 30 日

A Study to Compare Eribulin Mesylate + Pertuzumab + Trastuzumab With Paclitaxel or Docetaxel + Pertuzumab + Trastuzumab

计划入组 446 人 · 首次发布于 2017 年 8 月 29 日

Elderly Metastatic Breast Cancer: Pertuzumab-Herceptin vs Pertuzumab-Herceptin-Metronomic Chemotherapy, Followed by T-DM1

计划入组 80 人 · 首次发布于 2012 年 5 月 14 日

Pertuzumab(Perjeta, Perjeta-Herceptin, Phesgo)

89Zr-pertuzumab

Pertuzumab zuvotolimod

FDA Approves First Interchangeable Biosimilar to Pertuzumab for HER2-Positive Breast Cancer

FDA Approves First Perjeta Biosimilar as Shanghai Henlius and Organon Secure Interchangeable Status

FDA Approves Wave of Oncology Drugs and Biosimilars in November 2025, Expanding Treatment Access